Vaccines; Modified cells for medical or clinical use; Pharmaceuticals for the prevention or treatment of COVID19; Pharmaceuticals for the prevention or treatment of infection with respiratory syncytial virus (RSV); Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for medical use; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing infection, disease, or disorders; Medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for treating infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention of infection, disease, or disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of infection, disease, or disorders
Pharmaceuticals